Tscan Therapeutics Net Worth
Tscan Therapeutics Net Worth Breakdown | TCRX |
Tscan Therapeutics Net Worth Analysis
Tscan Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Tscan Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Tscan Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Tscan Therapeutics' net worth analysis. One common approach is to calculate Tscan Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Tscan Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Tscan Therapeutics' net worth. This approach calculates the present value of Tscan Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Tscan Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Tscan Therapeutics' net worth. This involves comparing Tscan Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Tscan Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Tscan Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Tscan Therapeutics' net worth research are outlined below:
| Tscan Therapeutics had very high historical volatility over the last 90 days | |
| Tscan Therapeutics may become a speculative penny stock | |
| Tscan Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 2.82 M. Net Loss for the year was (127.5 M) with loss before overhead, payroll, taxes, and interest of (5.36 M). | |
| Tscan Therapeutics currently holds about 125.6 M in cash with (110.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Tscan Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 88.0% of the company shares are owned by institutional investors | |
| Latest headline from simplywall.st: Great week for TScan Therapeutics, Inc. institutional investors after losing 73 percent over the previous year |
Tscan Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Tscan Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Tscan Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 13th of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 13th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Tscan Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Tscan Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Tscan Therapeutics backward and forwards among themselves. Tscan Therapeutics' institutional investor refers to the entity that pools money to purchase Tscan Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | State Street Corp | 2025-03-31 | 817.2 K | Ecor1 Capital, Llc | 2025-03-31 | 662.8 K | Dc Funds, Lp | 2025-03-31 | 630 K | Tang Capital Management Llc | 2025-03-31 | 600 K | Morgan Stanley - Brokerage Accounts | 2025-03-31 | 593 K | Northern Trust Corp | 2025-03-31 | 330 K | Dimensional Fund Advisors, Inc. | 2025-03-31 | 270.1 K | Jpmorgan Chase & Co | 2025-03-31 | 265.1 K | Millennium Management Llc | 2025-03-31 | 231.2 K | Bvf Inc | 2025-03-31 | 4.9 M | Blackrock Inc | 2025-03-31 | 4.9 M |
Follow Tscan Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 102.99 M.Market Cap |
|
Project Tscan Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.34) | (0.36) | |
| Return On Capital Employed | (0.40) | (0.42) | |
| Return On Assets | (0.34) | (0.36) | |
| Return On Equity | (0.53) | (0.50) |
When accessing Tscan Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Tscan Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Tscan Therapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Tscan Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Tscan Therapeutics. Check Tscan Therapeutics' Beneish M Score to see the likelihood of Tscan Therapeutics' management manipulating its earnings.
Evaluate Tscan Therapeutics' management efficiency
Tscan Therapeutics has return on total asset (ROA) of (0.3045) % which means that it has lost $0.3045 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7893) %, meaning that it created substantial loss on money invested by shareholders. Tscan Therapeutics' management efficiency ratios could be used to measure how well Tscan Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.36 in 2025. Return On Capital Employed is likely to drop to -0.42 in 2025. At this time, Tscan Therapeutics' Net Tangible Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 3.6 M in 2025, whereas Total Assets are likely to drop slightly above 207.1 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.15 | 1.72 | |
| Tangible Book Value Per Share | 2.15 | 1.72 | |
| Enterprise Value Over EBITDA | (2.16) | (2.27) | |
| Price Book Value Ratio | 1.41 | 1.48 | |
| Enterprise Value Multiple | (2.16) | (2.27) | |
| Price Fair Value | 1.41 | 1.48 | |
| Enterprise Value | 259.1 M | 272.1 M |
The strategic initiatives led by Tscan Therapeutics' management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Enterprise Value Revenue 7.6417 | Revenue | Quarterly Revenue Growth 2.836 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Tscan Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Tscan Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Tscan Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Tscan Therapeutics time-series forecasting models is one of many Tscan Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Tscan Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Tscan Therapeutics Earnings per Share Projection vs Actual
Tscan Therapeutics Corporate Management
| Justin McCue | Chief Officer | Profile | |
| Leiden MBA | Principal Treasurer | Profile | |
| Stephen Camiolo | Senior Access | Profile | |
| Ray Lockard | VP Quality | Profile | |
| Ray MBA | Senior Quality | Profile |
Additional Tools for Tscan Stock Analysis
When running Tscan Therapeutics' price analysis, check to measure Tscan Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tscan Therapeutics is operating at the current time. Most of Tscan Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tscan Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tscan Therapeutics' price. Additionally, you may evaluate how the addition of Tscan Therapeutics to your portfolios can decrease your overall portfolio volatility.